Illumina (ILMN) announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina’s strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, understand biological pathways, discover novel disease mechanisms, and build the next wave of biological insights. This move reflects Illumina’s commitment to delivering innovative solutions to advance science and health care, and fuels the company’s long-term, sustainable growth. BioInsight will be led by Rami Mehio as senior vice president and general manager. Mehio has led Illumina’s Global Software & Informatics team for four years and now joins the company’s executive leadership team.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina to partner with multiple global pharmaceutical companies
- Illumina price target lowered to $124 from $126 at RBC Capital
- Cathie Wood Buys Deere Stock (DE) on Post-Earnings Dip, Builds Stakes in Exact Sciences and Robinhood Stocks
- Icahn exits Illumina, Dana; boosts stakes in CVR Energy
- Illumina downgraded to Neutral from Outperform at Daiwa